Healthcare Industry News: NS5A
News Release - August 5, 2009
Dr. Nathaniel Brown Joins Presidio Pharmaceuticals, Inc. as Senior Vice President of Clinical DevelopmentSAN FRANCISCO--(HSMN NewsFeed)--Presidio Pharmaceuticals, Inc. is pleased to announce that Dr. Nathaniel Brown has joined the Company as Senior Vice President of Clinical Development.
“Nat has had a stellar career and brings to the Company a wealth of experience and expertise in the clinical development of small molecule therapeutics for treating patients with HCV, HBV and HIV,” said Omar Haffar, President and CEO. “Having Nat join Presidio’s management team as we work toward clinical development of our NS5A clinical candidate for treating HCV is a great achievement for us. I look forward to working with Nat and the rest of the team in building a strong and integrated Company.”
Dr. Brown was previously Executive Vice President of Clinical Development and Chief Medical Officer at Idenix Pharmaceuticals, where he was responsible for the development of telbuvidine and valtorcitabine for HBV and valopicitabine for HCV. Prior to Idenix, Dr. Brown was Director of Clinical and Scientific Affairs for Infectious Disease and Hepatitis at Glaxo Wellcome, Inc. During his 20 years in clinical drug development, Dr. Brown has had leadership roles in six antiviral/anti-infective development programs, which led to successful product registrations in the U.S. and globally.
Dr. Brown studied Molecular Biophysics and Biochemistry at Yale University as an undergraduate. He received his Medical Degree from Georgetown University, School of Medicine, and subsequently completed his clinical specialty training and post-doctoral research at the New York Hospital-Cornell Medical Center and Yale University School of Medicine. He has authored over 180 scientific publications related to clinical virology and antiviral development, has served in advisory roles to various companies and government agencies (NIH and FDA), and has received leadership awards from the Hepatitis B Foundation and the American Liver Foundation.
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV-1 and HCV. For more information, please visit our website at www.presidiopharma.com.
Source: Presidio Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.